hargapennslammer3| Fuhong Hanlius now rises more than 5% and the international multi-center Phase III clinical trial of HLX22 has been approved in the United States

　　复宏汉霖（02696）早盘上涨5hargapennslammer3.05%hargapennslammer3，现报17hargapennslammer3.46港元hargapennslammer3，成交额379.10万港元。

　　复宏汉霖宣布，公司创新型抗HER2单抗HLX22的国际多中心III期的新药临床试验（IND）申请已经获得美国FDA许可，拟用于联合曲妥珠单抗及化疗一线治疗HER2阳性晚期胃癌。目前，全球尚无同类用于治疗HER2阳性胃癌的HER2双靶向疗法获批准上市。

Tags:

Prev: bestandroidgamestoearncrypto| Insurance Daily on May 7 丨 The overall net profit of A-share listed insurance companies fell by 9.16% in the first quarter, and BYD Property Insurance entered the new energy auto insurance market.
Next: depositcasino| How long is the maintenance cycle for Accord cars?